Valuation

JNJJohnson & Johnson

StockNYSEUnited StatesHealth careEU retail investors: available

+2.1% today · +54.6% over a year

8/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 86% of the instruments we score

Trend, Stability: among the best of its peers. Dividend yield 1.87%.

Johnson & Johnson (JNJ) valuation against sector peers: P/E 42.2 (sector median 30.9), P/B 8.3, free-cash-flow yield 3.0%, P/S 6.8.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricJNJSector medianvs median
P/E42.230.9 · n=15936% above
P/B8.34.0 · n=307111% above
P/S6.84.1 · n=29965% above
EV/EBIT—25.6 · n=146—
Free-cash-flow yield3.0%1.4% · n=288110% above
Dividend yield1.87%0.00% · n=362—
Return on equity20.0%−2.1% · n=308—
Return on invested capital—0.6% · n=282—
Gross margin67.6%63.3% · n=2057% above
Net debt / EBITDA—1.27 · n=151—

Value factor: 55 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.233.0—1.5%0.6%6/10
ABBVAbbVie50.3—27.73.6%2.9%6/10
MRKMerck149.58.2—4.0%2.3%8/10
UNHUnitedHealth22.43.417.16.4%2.3%10/10
TMOThermo Fisher Scientific37.84.935.72.8%0.3%9/10
AMGNAmgen26.817.523.23.8%2.1%8/10
GILDGilead Sciences—16.1—6.6%1.9%5/10
ABTAbbott40.73.832.93.5%2.8%6/10
PFEPfizer41.31.9—7.1%7.4%1/10
DHRDanaher38.23.135.73.5%0.6%7/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 27 Sep 2026 · filed 21 Oct 2026